Global Platinum Anti-tumor Drugs Market Research Report 2023
Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.
According to QYResearch’s new survey, global Platinum Anti-tumor Drugs market is projected to reach US$ 1876.8 million in 2029, increasing from US$ 1527 million in 2022, with the CAGR of 2.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Platinum Anti-tumor Drugs market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Platinum Anti-tumor Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
According to QYResearch’s new survey, global Platinum Anti-tumor Drugs market is projected to reach US$ 1876.8 million in 2029, increasing from US$ 1527 million in 2022, with the CAGR of 2.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Platinum Anti-tumor Drugs market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Platinum Anti-tumor Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- Sanofi
- Hengrui Medicine
- ASK Pharma
- Yi Bai Pharmaceutical
- Qilu Pharmaceutical
- Teva
- Pfizer
- Dr Reddy's Laboratories
- Viatris
- Sun Pharma
- Novartis
- Debiopharm
- Accord Healthcare
- SK Chemicals
- Cisplatin
- Oxaliplatin
- Carboplatin
- Other
- Colorectal Cancer
- Ovarian Cancer
- Lung Cancer
- Other
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Platinum Anti-tumor Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Cisplatin
1.2.3 Oxaliplatin
1.2.4 Carboplatin
1.2.5 Other
1.3 Market by Application
1.3.1 Global Platinum Anti-tumor Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Colorectal Cancer
1.3.3 Ovarian Cancer
1.3.4 Lung Cancer
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Platinum Anti-tumor Drugs Market Perspective (2018-2029)
2.2 Platinum Anti-tumor Drugs Growth Trends by Region
2.2.1 Global Platinum Anti-tumor Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Platinum Anti-tumor Drugs Historic Market Size by Region (2018-2023)
2.2.3 Platinum Anti-tumor Drugs Forecasted Market Size by Region (2024-2029)
2.3 Platinum Anti-tumor Drugs Market Dynamics
2.3.1 Platinum Anti-tumor Drugs Industry Trends
2.3.2 Platinum Anti-tumor Drugs Market Drivers
2.3.3 Platinum Anti-tumor Drugs Market Challenges
2.3.4 Platinum Anti-tumor Drugs Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Platinum Anti-tumor Drugs Players by Revenue
3.1.1 Global Top Platinum Anti-tumor Drugs Players by Revenue (2018-2023)
3.1.2 Global Platinum Anti-tumor Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Platinum Anti-tumor Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Platinum Anti-tumor Drugs Revenue
3.4 Global Platinum Anti-tumor Drugs Market Concentration Ratio
3.4.1 Global Platinum Anti-tumor Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Platinum Anti-tumor Drugs Revenue in 2022
3.5 Platinum Anti-tumor Drugs Key Players Head office and Area Served
3.6 Key Players Platinum Anti-tumor Drugs Product Solution and Service
3.7 Date of Enter into Platinum Anti-tumor Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 PLATINUM ANTI-TUMOR DRUGS BREAKDOWN DATA BY TYPE
4.1 Global Platinum Anti-tumor Drugs Historic Market Size by Type (2018-2023)
4.2 Global Platinum Anti-tumor Drugs Forecasted Market Size by Type (2024-2029)
5 PLATINUM ANTI-TUMOR DRUGS BREAKDOWN DATA BY APPLICATION
5.1 Global Platinum Anti-tumor Drugs Historic Market Size by Application (2018-2023)
5.2 Global Platinum Anti-tumor Drugs Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Platinum Anti-tumor Drugs Market Size (2018-2029)
6.2 North America Platinum Anti-tumor Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Platinum Anti-tumor Drugs Market Size by Country (2018-2023)
6.4 North America Platinum Anti-tumor Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Platinum Anti-tumor Drugs Market Size (2018-2029)
7.2 Europe Platinum Anti-tumor Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Platinum Anti-tumor Drugs Market Size by Country (2018-2023)
7.4 Europe Platinum Anti-tumor Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Platinum Anti-tumor Drugs Market Size (2018-2029)
8.2 Asia-Pacific Platinum Anti-tumor Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Platinum Anti-tumor Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Platinum Anti-tumor Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Platinum Anti-tumor Drugs Market Size (2018-2029)
9.2 Latin America Platinum Anti-tumor Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Platinum Anti-tumor Drugs Market Size by Country (2018-2023)
9.4 Latin America Platinum Anti-tumor Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Platinum Anti-tumor Drugs Market Size (2018-2029)
10.2 Middle East & Africa Platinum Anti-tumor Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Platinum Anti-tumor Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Platinum Anti-tumor Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Sanofi
11.1.1 Sanofi Company Detail
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Platinum Anti-tumor Drugs Introduction
11.1.4 Sanofi Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.1.5 Sanofi Recent Development
11.2 Hengrui Medicine
11.2.1 Hengrui Medicine Company Detail
11.2.2 Hengrui Medicine Business Overview
11.2.3 Hengrui Medicine Platinum Anti-tumor Drugs Introduction
11.2.4 Hengrui Medicine Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.2.5 Hengrui Medicine Recent Development
11.3 ASK Pharma
11.3.1 ASK Pharma Company Detail
11.3.2 ASK Pharma Business Overview
11.3.3 ASK Pharma Platinum Anti-tumor Drugs Introduction
11.3.4 ASK Pharma Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.3.5 ASK Pharma Recent Development
11.4 Yi Bai Pharmaceutical
11.4.1 Yi Bai Pharmaceutical Company Detail
11.4.2 Yi Bai Pharmaceutical Business Overview
11.4.3 Yi Bai Pharmaceutical Platinum Anti-tumor Drugs Introduction
11.4.4 Yi Bai Pharmaceutical Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.4.5 Yi Bai Pharmaceutical Recent Development
11.5 Qilu Pharmaceutical
11.5.1 Qilu Pharmaceutical Company Detail
11.5.2 Qilu Pharmaceutical Business Overview
11.5.3 Qilu Pharmaceutical Platinum Anti-tumor Drugs Introduction
11.5.4 Qilu Pharmaceutical Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.5.5 Qilu Pharmaceutical Recent Development
11.6 Teva
11.6.1 Teva Company Detail
11.6.2 Teva Business Overview
11.6.3 Teva Platinum Anti-tumor Drugs Introduction
11.6.4 Teva Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.6.5 Teva Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Platinum Anti-tumor Drugs Introduction
11.7.4 Pfizer Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.7.5 Pfizer Recent Development
11.8 Dr Reddy's Laboratories
11.8.1 Dr Reddy's Laboratories Company Detail
11.8.2 Dr Reddy's Laboratories Business Overview
11.8.3 Dr Reddy's Laboratories Platinum Anti-tumor Drugs Introduction
11.8.4 Dr Reddy's Laboratories Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.8.5 Dr Reddy's Laboratories Recent Development
11.9 Viatris
11.9.1 Viatris Company Detail
11.9.2 Viatris Business Overview
11.9.3 Viatris Platinum Anti-tumor Drugs Introduction
11.9.4 Viatris Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.9.5 Viatris Recent Development
11.10 Sun Pharma
11.10.1 Sun Pharma Company Detail
11.10.2 Sun Pharma Business Overview
11.10.3 Sun Pharma Platinum Anti-tumor Drugs Introduction
11.10.4 Sun Pharma Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.10.5 Sun Pharma Recent Development
11.11 Novartis
11.11.1 Novartis Company Detail
11.11.2 Novartis Business Overview
11.11.3 Novartis Platinum Anti-tumor Drugs Introduction
11.11.4 Novartis Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.11.5 Novartis Recent Development
11.12 Debiopharm
11.12.1 Debiopharm Company Detail
11.12.2 Debiopharm Business Overview
11.12.3 Debiopharm Platinum Anti-tumor Drugs Introduction
11.12.4 Debiopharm Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.12.5 Debiopharm Recent Development
11.13 Accord Healthcare
11.13.1 Accord Healthcare Company Detail
11.13.2 Accord Healthcare Business Overview
11.13.3 Accord Healthcare Platinum Anti-tumor Drugs Introduction
11.13.4 Accord Healthcare Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.13.5 Accord Healthcare Recent Development
11.14 SK Chemicals
11.14.1 SK Chemicals Company Detail
11.14.2 SK Chemicals Business Overview
11.14.3 SK Chemicals Platinum Anti-tumor Drugs Introduction
11.14.4 SK Chemicals Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.14.5 SK Chemicals Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Platinum Anti-tumor Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Cisplatin
1.2.3 Oxaliplatin
1.2.4 Carboplatin
1.2.5 Other
1.3 Market by Application
1.3.1 Global Platinum Anti-tumor Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Colorectal Cancer
1.3.3 Ovarian Cancer
1.3.4 Lung Cancer
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Platinum Anti-tumor Drugs Market Perspective (2018-2029)
2.2 Platinum Anti-tumor Drugs Growth Trends by Region
2.2.1 Global Platinum Anti-tumor Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Platinum Anti-tumor Drugs Historic Market Size by Region (2018-2023)
2.2.3 Platinum Anti-tumor Drugs Forecasted Market Size by Region (2024-2029)
2.3 Platinum Anti-tumor Drugs Market Dynamics
2.3.1 Platinum Anti-tumor Drugs Industry Trends
2.3.2 Platinum Anti-tumor Drugs Market Drivers
2.3.3 Platinum Anti-tumor Drugs Market Challenges
2.3.4 Platinum Anti-tumor Drugs Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Platinum Anti-tumor Drugs Players by Revenue
3.1.1 Global Top Platinum Anti-tumor Drugs Players by Revenue (2018-2023)
3.1.2 Global Platinum Anti-tumor Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Platinum Anti-tumor Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Platinum Anti-tumor Drugs Revenue
3.4 Global Platinum Anti-tumor Drugs Market Concentration Ratio
3.4.1 Global Platinum Anti-tumor Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Platinum Anti-tumor Drugs Revenue in 2022
3.5 Platinum Anti-tumor Drugs Key Players Head office and Area Served
3.6 Key Players Platinum Anti-tumor Drugs Product Solution and Service
3.7 Date of Enter into Platinum Anti-tumor Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 PLATINUM ANTI-TUMOR DRUGS BREAKDOWN DATA BY TYPE
4.1 Global Platinum Anti-tumor Drugs Historic Market Size by Type (2018-2023)
4.2 Global Platinum Anti-tumor Drugs Forecasted Market Size by Type (2024-2029)
5 PLATINUM ANTI-TUMOR DRUGS BREAKDOWN DATA BY APPLICATION
5.1 Global Platinum Anti-tumor Drugs Historic Market Size by Application (2018-2023)
5.2 Global Platinum Anti-tumor Drugs Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Platinum Anti-tumor Drugs Market Size (2018-2029)
6.2 North America Platinum Anti-tumor Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Platinum Anti-tumor Drugs Market Size by Country (2018-2023)
6.4 North America Platinum Anti-tumor Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Platinum Anti-tumor Drugs Market Size (2018-2029)
7.2 Europe Platinum Anti-tumor Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Platinum Anti-tumor Drugs Market Size by Country (2018-2023)
7.4 Europe Platinum Anti-tumor Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Platinum Anti-tumor Drugs Market Size (2018-2029)
8.2 Asia-Pacific Platinum Anti-tumor Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Platinum Anti-tumor Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Platinum Anti-tumor Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Platinum Anti-tumor Drugs Market Size (2018-2029)
9.2 Latin America Platinum Anti-tumor Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Platinum Anti-tumor Drugs Market Size by Country (2018-2023)
9.4 Latin America Platinum Anti-tumor Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Platinum Anti-tumor Drugs Market Size (2018-2029)
10.2 Middle East & Africa Platinum Anti-tumor Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Platinum Anti-tumor Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Platinum Anti-tumor Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Sanofi
11.1.1 Sanofi Company Detail
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Platinum Anti-tumor Drugs Introduction
11.1.4 Sanofi Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.1.5 Sanofi Recent Development
11.2 Hengrui Medicine
11.2.1 Hengrui Medicine Company Detail
11.2.2 Hengrui Medicine Business Overview
11.2.3 Hengrui Medicine Platinum Anti-tumor Drugs Introduction
11.2.4 Hengrui Medicine Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.2.5 Hengrui Medicine Recent Development
11.3 ASK Pharma
11.3.1 ASK Pharma Company Detail
11.3.2 ASK Pharma Business Overview
11.3.3 ASK Pharma Platinum Anti-tumor Drugs Introduction
11.3.4 ASK Pharma Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.3.5 ASK Pharma Recent Development
11.4 Yi Bai Pharmaceutical
11.4.1 Yi Bai Pharmaceutical Company Detail
11.4.2 Yi Bai Pharmaceutical Business Overview
11.4.3 Yi Bai Pharmaceutical Platinum Anti-tumor Drugs Introduction
11.4.4 Yi Bai Pharmaceutical Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.4.5 Yi Bai Pharmaceutical Recent Development
11.5 Qilu Pharmaceutical
11.5.1 Qilu Pharmaceutical Company Detail
11.5.2 Qilu Pharmaceutical Business Overview
11.5.3 Qilu Pharmaceutical Platinum Anti-tumor Drugs Introduction
11.5.4 Qilu Pharmaceutical Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.5.5 Qilu Pharmaceutical Recent Development
11.6 Teva
11.6.1 Teva Company Detail
11.6.2 Teva Business Overview
11.6.3 Teva Platinum Anti-tumor Drugs Introduction
11.6.4 Teva Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.6.5 Teva Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Platinum Anti-tumor Drugs Introduction
11.7.4 Pfizer Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.7.5 Pfizer Recent Development
11.8 Dr Reddy's Laboratories
11.8.1 Dr Reddy's Laboratories Company Detail
11.8.2 Dr Reddy's Laboratories Business Overview
11.8.3 Dr Reddy's Laboratories Platinum Anti-tumor Drugs Introduction
11.8.4 Dr Reddy's Laboratories Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.8.5 Dr Reddy's Laboratories Recent Development
11.9 Viatris
11.9.1 Viatris Company Detail
11.9.2 Viatris Business Overview
11.9.3 Viatris Platinum Anti-tumor Drugs Introduction
11.9.4 Viatris Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.9.5 Viatris Recent Development
11.10 Sun Pharma
11.10.1 Sun Pharma Company Detail
11.10.2 Sun Pharma Business Overview
11.10.3 Sun Pharma Platinum Anti-tumor Drugs Introduction
11.10.4 Sun Pharma Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.10.5 Sun Pharma Recent Development
11.11 Novartis
11.11.1 Novartis Company Detail
11.11.2 Novartis Business Overview
11.11.3 Novartis Platinum Anti-tumor Drugs Introduction
11.11.4 Novartis Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.11.5 Novartis Recent Development
11.12 Debiopharm
11.12.1 Debiopharm Company Detail
11.12.2 Debiopharm Business Overview
11.12.3 Debiopharm Platinum Anti-tumor Drugs Introduction
11.12.4 Debiopharm Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.12.5 Debiopharm Recent Development
11.13 Accord Healthcare
11.13.1 Accord Healthcare Company Detail
11.13.2 Accord Healthcare Business Overview
11.13.3 Accord Healthcare Platinum Anti-tumor Drugs Introduction
11.13.4 Accord Healthcare Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.13.5 Accord Healthcare Recent Development
11.14 SK Chemicals
11.14.1 SK Chemicals Company Detail
11.14.2 SK Chemicals Business Overview
11.14.3 SK Chemicals Platinum Anti-tumor Drugs Introduction
11.14.4 SK Chemicals Revenue in Platinum Anti-tumor Drugs Business (2018-2023)
11.14.5 SK Chemicals Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Platinum Anti-tumor Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Cisplatin
Table 3. Key Players of Oxaliplatin
Table 4. Key Players of Carboplatin
Table 5. Key Players of Other
Table 6. Global Platinum Anti-tumor Drugs Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Platinum Anti-tumor Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Platinum Anti-tumor Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Platinum Anti-tumor Drugs Market Share by Region (2018-2023)
Table 10. Global Platinum Anti-tumor Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Platinum Anti-tumor Drugs Market Share by Region (2024-2029)
Table 12. Platinum Anti-tumor Drugs Market Trends
Table 13. Platinum Anti-tumor Drugs Market Drivers
Table 14. Platinum Anti-tumor Drugs Market Challenges
Table 15. Platinum Anti-tumor Drugs Market Restraints
Table 16. Global Platinum Anti-tumor Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Platinum Anti-tumor Drugs Market Share by Players (2018-2023)
Table 18. Global Top Platinum Anti-tumor Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Platinum Anti-tumor Drugs as of 2022)
Table 19. Ranking of Global Top Platinum Anti-tumor Drugs Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Platinum Anti-tumor Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Platinum Anti-tumor Drugs Product Solution and Service
Table 23. Date of Enter into Platinum Anti-tumor Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Platinum Anti-tumor Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Platinum Anti-tumor Drugs Revenue Market Share by Type (2018-2023)
Table 27. Global Platinum Anti-tumor Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Platinum Anti-tumor Drugs Revenue Market Share by Type (2024-2029)
Table 29. Global Platinum Anti-tumor Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Platinum Anti-tumor Drugs Revenue Market Share by Application (2018-2023)
Table 31. Global Platinum Anti-tumor Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Platinum Anti-tumor Drugs Revenue Market Share by Application (2024-2029)
Table 33. North America Platinum Anti-tumor Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 34. North America Platinum Anti-tumor Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Platinum Anti-tumor Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 36. Europe Platinum Anti-tumor Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. Europe Platinum Anti-tumor Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Platinum Anti-tumor Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 39. Asia-Pacific Platinum Anti-tumor Drugs Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 40. Asia-Pacific Platinum Anti-tumor Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Platinum Anti-tumor Drugs Market Size by Region (2024-2029) & (US$ Million)
Table 42. Latin America Platinum Anti-tumor Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Latin America Platinum Anti-tumor Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Platinum Anti-tumor Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Platinum Anti-tumor Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Middle East & Africa Platinum Anti-tumor Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Platinum Anti-tumor Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 48. Sanofi Company Detail
Table 49. Sanofi Business Overview
Table 50. Sanofi Platinum Anti-tumor Drugs Product
Table 51. Sanofi Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 52. Sanofi Recent Development
Table 53. Hengrui Medicine Company Detail
Table 54. Hengrui Medicine Business Overview
Table 55. Hengrui Medicine Platinum Anti-tumor Drugs Product
Table 56. Hengrui Medicine Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 57. Hengrui Medicine Recent Development
Table 58. ASK Pharma Company Detail
Table 59. ASK Pharma Business Overview
Table 60. ASK Pharma Platinum Anti-tumor Drugs Product
Table 61. ASK Pharma Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 62. ASK Pharma Recent Development
Table 63. Yi Bai Pharmaceutical Company Detail
Table 64. Yi Bai Pharmaceutical Business Overview
Table 65. Yi Bai Pharmaceutical Platinum Anti-tumor Drugs Product
Table 66. Yi Bai Pharmaceutical Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 67. Yi Bai Pharmaceutical Recent Development
Table 68. Qilu Pharmaceutical Company Detail
Table 69. Qilu Pharmaceutical Business Overview
Table 70. Qilu Pharmaceutical Platinum Anti-tumor Drugs Product
Table 71. Qilu Pharmaceutical Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 72. Qilu Pharmaceutical Recent Development
Table 73. Teva Company Detail
Table 74. Teva Business Overview
Table 75. Teva Platinum Anti-tumor Drugs Product
Table 76. Teva Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 77. Teva Recent Development
Table 78. Pfizer Company Detail
Table 79. Pfizer Business Overview
Table 80. Pfizer Platinum Anti-tumor Drugs Product
Table 81. Pfizer Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 82. Pfizer Recent Development
Table 83. Dr Reddy's Laboratories Company Detail
Table 84. Dr Reddy's Laboratories Business Overview
Table 85. Dr Reddy's Laboratories Platinum Anti-tumor Drugs Product
Table 86. Dr Reddy's Laboratories Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 87. Dr Reddy's Laboratories Recent Development
Table 88. Viatris Company Detail
Table 89. Viatris Business Overview
Table 90. Viatris Platinum Anti-tumor Drugs Product
Table 91. Viatris Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 92. Viatris Recent Development
Table 93. Sun Pharma Company Detail
Table 94. Sun Pharma Business Overview
Table 95. Sun Pharma Platinum Anti-tumor Drugs Product
Table 96. Sun Pharma Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 97. Sun Pharma Recent Development
Table 98. Novartis Company Detail
Table 99. Novartis Business Overview
Table 100. Novartis Platinum Anti-tumor Drugs Product
Table 101. Novartis Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 102. Novartis Recent Development
Table 103. Debiopharm Company Detail
Table 104. Debiopharm Business Overview
Table 105. Debiopharm Platinum Anti-tumor Drugs Product
Table 106. Debiopharm Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 107. Debiopharm Recent Development
Table 108. Accord Healthcare Company Detail
Table 109. Accord Healthcare Business Overview
Table 110. Accord Healthcare Platinum Anti-tumor Drugs Product
Table 111. Accord Healthcare Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 112. Accord Healthcare Recent Development
Table 113. SK Chemicals Company Detail
Table 114. SK Chemicals Business Overview
Table 115. SK Chemicals Platinum Anti-tumor Drugs Product
Table 116. SK Chemicals Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 117. SK Chemicals Recent Development
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
Table 1. Global Platinum Anti-tumor Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Cisplatin
Table 3. Key Players of Oxaliplatin
Table 4. Key Players of Carboplatin
Table 5. Key Players of Other
Table 6. Global Platinum Anti-tumor Drugs Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Platinum Anti-tumor Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Platinum Anti-tumor Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Platinum Anti-tumor Drugs Market Share by Region (2018-2023)
Table 10. Global Platinum Anti-tumor Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Platinum Anti-tumor Drugs Market Share by Region (2024-2029)
Table 12. Platinum Anti-tumor Drugs Market Trends
Table 13. Platinum Anti-tumor Drugs Market Drivers
Table 14. Platinum Anti-tumor Drugs Market Challenges
Table 15. Platinum Anti-tumor Drugs Market Restraints
Table 16. Global Platinum Anti-tumor Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Platinum Anti-tumor Drugs Market Share by Players (2018-2023)
Table 18. Global Top Platinum Anti-tumor Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Platinum Anti-tumor Drugs as of 2022)
Table 19. Ranking of Global Top Platinum Anti-tumor Drugs Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Platinum Anti-tumor Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Platinum Anti-tumor Drugs Product Solution and Service
Table 23. Date of Enter into Platinum Anti-tumor Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Platinum Anti-tumor Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Platinum Anti-tumor Drugs Revenue Market Share by Type (2018-2023)
Table 27. Global Platinum Anti-tumor Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Platinum Anti-tumor Drugs Revenue Market Share by Type (2024-2029)
Table 29. Global Platinum Anti-tumor Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Platinum Anti-tumor Drugs Revenue Market Share by Application (2018-2023)
Table 31. Global Platinum Anti-tumor Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Platinum Anti-tumor Drugs Revenue Market Share by Application (2024-2029)
Table 33. North America Platinum Anti-tumor Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 34. North America Platinum Anti-tumor Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Platinum Anti-tumor Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 36. Europe Platinum Anti-tumor Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. Europe Platinum Anti-tumor Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Platinum Anti-tumor Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 39. Asia-Pacific Platinum Anti-tumor Drugs Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 40. Asia-Pacific Platinum Anti-tumor Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Platinum Anti-tumor Drugs Market Size by Region (2024-2029) & (US$ Million)
Table 42. Latin America Platinum Anti-tumor Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Latin America Platinum Anti-tumor Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Platinum Anti-tumor Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Platinum Anti-tumor Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Middle East & Africa Platinum Anti-tumor Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Platinum Anti-tumor Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 48. Sanofi Company Detail
Table 49. Sanofi Business Overview
Table 50. Sanofi Platinum Anti-tumor Drugs Product
Table 51. Sanofi Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 52. Sanofi Recent Development
Table 53. Hengrui Medicine Company Detail
Table 54. Hengrui Medicine Business Overview
Table 55. Hengrui Medicine Platinum Anti-tumor Drugs Product
Table 56. Hengrui Medicine Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 57. Hengrui Medicine Recent Development
Table 58. ASK Pharma Company Detail
Table 59. ASK Pharma Business Overview
Table 60. ASK Pharma Platinum Anti-tumor Drugs Product
Table 61. ASK Pharma Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 62. ASK Pharma Recent Development
Table 63. Yi Bai Pharmaceutical Company Detail
Table 64. Yi Bai Pharmaceutical Business Overview
Table 65. Yi Bai Pharmaceutical Platinum Anti-tumor Drugs Product
Table 66. Yi Bai Pharmaceutical Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 67. Yi Bai Pharmaceutical Recent Development
Table 68. Qilu Pharmaceutical Company Detail
Table 69. Qilu Pharmaceutical Business Overview
Table 70. Qilu Pharmaceutical Platinum Anti-tumor Drugs Product
Table 71. Qilu Pharmaceutical Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 72. Qilu Pharmaceutical Recent Development
Table 73. Teva Company Detail
Table 74. Teva Business Overview
Table 75. Teva Platinum Anti-tumor Drugs Product
Table 76. Teva Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 77. Teva Recent Development
Table 78. Pfizer Company Detail
Table 79. Pfizer Business Overview
Table 80. Pfizer Platinum Anti-tumor Drugs Product
Table 81. Pfizer Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 82. Pfizer Recent Development
Table 83. Dr Reddy's Laboratories Company Detail
Table 84. Dr Reddy's Laboratories Business Overview
Table 85. Dr Reddy's Laboratories Platinum Anti-tumor Drugs Product
Table 86. Dr Reddy's Laboratories Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 87. Dr Reddy's Laboratories Recent Development
Table 88. Viatris Company Detail
Table 89. Viatris Business Overview
Table 90. Viatris Platinum Anti-tumor Drugs Product
Table 91. Viatris Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 92. Viatris Recent Development
Table 93. Sun Pharma Company Detail
Table 94. Sun Pharma Business Overview
Table 95. Sun Pharma Platinum Anti-tumor Drugs Product
Table 96. Sun Pharma Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 97. Sun Pharma Recent Development
Table 98. Novartis Company Detail
Table 99. Novartis Business Overview
Table 100. Novartis Platinum Anti-tumor Drugs Product
Table 101. Novartis Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 102. Novartis Recent Development
Table 103. Debiopharm Company Detail
Table 104. Debiopharm Business Overview
Table 105. Debiopharm Platinum Anti-tumor Drugs Product
Table 106. Debiopharm Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 107. Debiopharm Recent Development
Table 108. Accord Healthcare Company Detail
Table 109. Accord Healthcare Business Overview
Table 110. Accord Healthcare Platinum Anti-tumor Drugs Product
Table 111. Accord Healthcare Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 112. Accord Healthcare Recent Development
Table 113. SK Chemicals Company Detail
Table 114. SK Chemicals Business Overview
Table 115. SK Chemicals Platinum Anti-tumor Drugs Product
Table 116. SK Chemicals Revenue in Platinum Anti-tumor Drugs Business (2018-2023) & (US$ Million)
Table 117. SK Chemicals Recent Development
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Platinum Anti-tumor Drugs Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Platinum Anti-tumor Drugs Market Share by Type: 2022 VS 2029
Figure 3. Cisplatin Features
Figure 4. Oxaliplatin Features
Figure 5. Carboplatin Features
Figure 6. Other Features
Figure 7. Global Platinum Anti-tumor Drugs Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 8. Global Platinum Anti-tumor Drugs Market Share by Application: 2022 VS 2029
Figure 9. Colorectal Cancer Case Studies
Figure 10. Ovarian Cancer Case Studies
Figure 11. Lung Cancer Case Studies
Figure 12. Other Case Studies
Figure 13. Platinum Anti-tumor Drugs Report Years Considered
Figure 14. Global Platinum Anti-tumor Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Platinum Anti-tumor Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Platinum Anti-tumor Drugs Market Share by Region: 2022 VS 2029
Figure 17. Global Platinum Anti-tumor Drugs Market Share by Players in 2022
Figure 18. Global Top Platinum Anti-tumor Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Platinum Anti-tumor Drugs as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Platinum Anti-tumor Drugs Revenue in 2022
Figure 20. North America Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Platinum Anti-tumor Drugs Market Share by Country (2018-2029)
Figure 22. United States Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Platinum Anti-tumor Drugs Market Share by Country (2018-2029)
Figure 26. Germany Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. France Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. U.K. Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Italy Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Russia Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Nordic Countries Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Platinum Anti-tumor Drugs Market Share by Region (2018-2029)
Figure 34. China Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Japan Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. South Korea Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Southeast Asia Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. India Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Australia Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Platinum Anti-tumor Drugs Market Share by Country (2018-2029)
Figure 42. Mexico Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Brazil Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Platinum Anti-tumor Drugs Market Share by Country (2018-2029)
Figure 46. Turkey Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Saudi Arabia Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Sanofi Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 49. Hengrui Medicine Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 50. ASK Pharma Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 51. Yi Bai Pharmaceutical Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 52. Qilu Pharmaceutical Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 53. Teva Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 54. Pfizer Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 55. Dr Reddy's Laboratories Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 56. Viatris Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 57. Sun Pharma Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 58. Novartis Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 59. Debiopharm Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 60. Accord Healthcare Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 61. SK Chemicals Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Figure 1. Global Platinum Anti-tumor Drugs Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Platinum Anti-tumor Drugs Market Share by Type: 2022 VS 2029
Figure 3. Cisplatin Features
Figure 4. Oxaliplatin Features
Figure 5. Carboplatin Features
Figure 6. Other Features
Figure 7. Global Platinum Anti-tumor Drugs Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 8. Global Platinum Anti-tumor Drugs Market Share by Application: 2022 VS 2029
Figure 9. Colorectal Cancer Case Studies
Figure 10. Ovarian Cancer Case Studies
Figure 11. Lung Cancer Case Studies
Figure 12. Other Case Studies
Figure 13. Platinum Anti-tumor Drugs Report Years Considered
Figure 14. Global Platinum Anti-tumor Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Platinum Anti-tumor Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Platinum Anti-tumor Drugs Market Share by Region: 2022 VS 2029
Figure 17. Global Platinum Anti-tumor Drugs Market Share by Players in 2022
Figure 18. Global Top Platinum Anti-tumor Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Platinum Anti-tumor Drugs as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Platinum Anti-tumor Drugs Revenue in 2022
Figure 20. North America Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Platinum Anti-tumor Drugs Market Share by Country (2018-2029)
Figure 22. United States Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Platinum Anti-tumor Drugs Market Share by Country (2018-2029)
Figure 26. Germany Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. France Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. U.K. Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Italy Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Russia Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Nordic Countries Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Platinum Anti-tumor Drugs Market Share by Region (2018-2029)
Figure 34. China Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Japan Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. South Korea Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Southeast Asia Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. India Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Australia Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Platinum Anti-tumor Drugs Market Share by Country (2018-2029)
Figure 42. Mexico Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Brazil Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Platinum Anti-tumor Drugs Market Share by Country (2018-2029)
Figure 46. Turkey Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Saudi Arabia Platinum Anti-tumor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Sanofi Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 49. Hengrui Medicine Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 50. ASK Pharma Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 51. Yi Bai Pharmaceutical Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 52. Qilu Pharmaceutical Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 53. Teva Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 54. Pfizer Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 55. Dr Reddy's Laboratories Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 56. Viatris Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 57. Sun Pharma Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 58. Novartis Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 59. Debiopharm Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 60. Accord Healthcare Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 61. SK Chemicals Revenue Growth Rate in Platinum Anti-tumor Drugs Business (2018-2023)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
